BioNTech SE

Headquarters: Mainz, Germany

Founded: 2008

Employees: 2,800

CEO: Prof. Ugur Sahin M.D.

FSX: 22UA -2.55%

Market Cap

€23.32 Billion

EUR as of Jan. 1, 2024

US$25.76 Billion

history Market Cap History

BioNTech SE market capitalization over time

Evolution of BioNTech SE market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of BioNTech SE

Detailed Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

BioNTech SE has the following listings and related stock indices.

Stock: FSX: 22UA wb_incandescent

Stock: NASDAQ: BNTX wb_incandescent

Stock: BMV: BNTXN wb_incandescent

Product & Services

BNT162b2, Immunotherapy

Key People

Founder(s): Uğur ŞahinÖzlem Türeci Christoph Huber Andreas Strüngmann Thomas Strüngmann Michael Motschmann Helmut Jeggle

Uğur Şahin (CEO)Özlem Türeci (CMO) Sean Marett (CBO, CCO) Sierk Poetting (CFO, COO) Ryan Richardson (CSO)


Revenue: €482.3 million (2020)

Operating income: €89.4 million (2020)

Net income: €366.9 million (2020)

Total assets: €2.3 billion (2020)

Total equity: €1.3 billion (2020)



An der Goldgrube 12

Mainz, 55131


Phone: 49 6131 9084 0

Fax: 49 6131 9084 390